Fortrea Holdings Inc. Common Stock (FTRE)
Stock · NASDAQ · Health Care
$22.51as of 10/16/2026
Price chart
Active signals
FTRE Signal Track Record
How signals performed across all stocks →What FTRE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 21 | -4.2% | 38% | September 14, 2026 |
| Bollinger Band Breakdown | 14 | -8.9% | 36% | September 8, 2026 |
| Bollinger Band BreakoutActive now | 11 | -1.6% | 45% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -5.7% | 25% | February 13, 2026 |
| Any 20-session window (baseline) | -2.7% | 45% |
Computed by MarketWall from daily closing prices since April 3, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 14,000
- Website
- www.fortrea.com/
Fundamentals
- 1-day range
- $21.63$23.07
- Market cap
- $1.68B
- P/E (trailing)
- —
- P/E (forward)
- 20.00
- EPS (trailing)
- $-0.91
- Dividend yield
- —
- Beta
- 1.93
- Avg. volume
- 1.53M
How Fortrea Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Fortrea Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FTREFortrea Holdings Inc. Common Stock$22.49▼ 1.12%Market cap $1.68BP/E —$8.55$23.51
- PSNLPersonalis Inc. Common Stock$15.65▼ 1.76%Market cap $1.39BP/E —$4.96$18.89
- TRUPTrupanion Inc. Common Stock$28.12▲ 0.93%Market cap $1.23BP/E 53.48$21.16$46.98
- FRNMFreenome Inc. Common stock$11.75▼ 4.35%Market cap $1.17BP/E —$9.97$17.5
- LMRILumexa Imaging Holdings Inc. Common Stock$10.78▲ 0.00%Market cap $1.10BP/E —$6.45$19.45
- CDNACareDx Inc. Common Stock$64▼ 4.01%Market cap $2.32BP/E 31.07$14.03$72.51
- CSTLCastle Biosciences Inc. Common Stock$31.96▼ 5.44%Market cap $930.84MP/E —$17.72$44.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FTRE Fortrea Holdings Inc. Common Stock | $1.68B | — | $22.49 | ▼ 1.12% | $8.55$23.51 |
| PSNL Personalis Inc. Common Stock | $1.39B | — | $15.65 | ▼ 1.76% | $4.96$18.89 |
| TRUP Trupanion Inc. Common Stock | $1.23B | 53.48 | $28.12 | ▲ 0.93% | $21.16$46.98 |
| FRNM Freenome Inc. Common stock | $1.17B | — | $11.75 | ▼ 4.35% | $9.97$17.5 |
| LMRI Lumexa Imaging Holdings Inc. Common Stock | $1.10B | — | $10.78 | ▲ 0.00% | $6.45$19.45 |
| CDNA CareDx Inc. Common Stock | $2.32B | 31.07 | $64 | ▼ 4.01% | $14.03$72.51 |
| CSTL Castle Biosciences Inc. Common Stock | $930.84M | — | $31.96 | ▼ 5.44% | $17.72$44.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Deutsche Bank Upgrades Fortrea Holdings to Buy, Raises Price Target to $25benzinga · 10/15/2026
- 3 Overrated Stocks We Think Twice AboutYahoo · 10/9/2026
- Fortrea (FTRE) Stock Trades Up, Here Is WhyYahoo · 10/6/2026
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On TuesdayBenzinga · 10/6/2026
- Barclays Upgrades Fortrea Holdings to Overweight, Raises Price Target to $23Benzinga · 10/6/2026
- 2 Volatile Stocks to Consider Right Now and 1 We Find RiskyYahoo · 10/5/2026
- Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference CallYahoo · 10/5/2026
- 1 Momentum Stock to Research Further and 2 We Turn DownYahoo · 10/2/2026
- 'HHS launches project to speed up clinical trials' - AxiosBenzinga · 9/30/2026
Insider Activity
Insider Actions →- Knoblauch Jason Fredrick · September 10, 2026 · Grant144.4K
- Russell Carrie Elizabeth · September 9, 2026 · Sale246 @ $16.85
- Morais Mark A. · September 9, 2026 · Sale3.1K @ $16.85
- Russell Carrie Elizabeth · September 8, 2026 · Option Exercise850
- Morais Mark A. · September 8, 2026 · Option Exercise7.2K
- Morais Mark A. · August 19, 2026 · Sale4.9K @ $18.19
- Morais Mark A. · August 18, 2026 · Option Exercise11.3K
- Thakral Anshul · August 6, 2026 · Sale56.0K @ $18.06
- Thakral Anshul · August 6, 2026 · Sale55.9K @ $18.17
- Thakral Anshul · August 5, 2026 · Sale50.4K @ $19.28
- Thakral Anshul · August 5, 2026 · Sale49.5K @ $19.03
- Thakral Anshul · August 4, 2026 · Option Exercise416.7K
- MacHelle Sanders · August 3, 2026 · Sale9.7K @ $18.01
- Smith David Ross · August 3, 2026 · Grant15.8K
- Smith David Ross · July 20, 2026 · Option Exercise6.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 95.43M
- Total value held
- $873.60M
- Institutional holders
- 323
- Unknown15.15M
- Unknown8.10M
- Unknown4.64M
- Unknown4.59M
- Unknown4.11M
- Unknown4.04M
- Unknown3.30M
- Unknown3.21M
- Unknown2.57M
- Unknown2.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23
Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.